Recro Pharma Priced, Nasdaq: REPH
Clinical-stage biotech developing non-opioid therapeutics for the treatment of pain.
Industry: Health Care
First Day Return: +3.8%
Industry: Health Care
REPH
Clinical-stage biotech developing non-opioid therapeutics for the treatment of pain.
| IPO Data | |
|---|---|
| IPO File Date | 10/24/2013 |
| Offer Price | $8.00 |
| Price Range $10.00 - $12.00 | |
| Offer Shares (mm) | 3.8 |
| Deal Size ($mm) | $30 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 03/06/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $30 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Malvern, PA, United States |
| Founded | 2008 |
| Employees at IPO | 5 |
| Website www.recropharma.com | |
IPO News for Recro Pharma
Recro Pharma (REPH) Performance
